IL163863A0 - Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz - Google Patents

Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz

Info

Publication number
IL163863A0
IL163863A0 IL16386303A IL16386303A IL163863A0 IL 163863 A0 IL163863 A0 IL 163863A0 IL 16386303 A IL16386303 A IL 16386303A IL 16386303 A IL16386303 A IL 16386303A IL 163863 A0 IL163863 A0 IL 163863A0
Authority
IL
Israel
Prior art keywords
methyl
phenylaminoümethylü
benzimidaz
for3
hexyloxycarbonylamino
Prior art date
Application number
IL16386303A
Other languages
English (en)
Original Assignee
Boehringer Sohn Ingelheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27789735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL163863(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10209985A external-priority patent/DE10209985A1/de
Priority claimed from DE2002145624 external-priority patent/DE10245624A1/de
Application filed by Boehringer Sohn Ingelheim filed Critical Boehringer Sohn Ingelheim
Publication of IL163863A0 publication Critical patent/IL163863A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16386303A 2002-03-07 2003-03-03 Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz IL163863A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10209985A DE10209985A1 (de) 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
DE2002145624 DE10245624A1 (de) 2002-09-30 2002-09-30 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze
PCT/EP2003/002141 WO2003074056A1 (de) 2002-03-07 2003-03-03 Oral zu applizierende darreichungsform für 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen salze

Publications (1)

Publication Number Publication Date
IL163863A0 true IL163863A0 (en) 2005-12-18

Family

ID=27789735

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16386303A IL163863A0 (en) 2002-03-07 2003-03-03 Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz
IL163863A IL163863A (en) 2002-03-07 2004-09-01 Pharmaceutical composition for oral administration of 3-[(2 -{[4- (hexyloxycarbonylamino- imino- methyl)-phenylamino]methyl}-1- methyl-1h- benzimidazol-5- carbonyl)- pyridin- 2- yl- amino] propionic acid ethyl ester
IL209368A IL209368A (en) 2002-03-07 2010-11-17 Ethylsulfonate Salt of Ethyl 3 - [(2– {4– (xyloxycarbonylamino – amino – methyl) –phenylamino] –methyl} –1 – methyl – H1– benzamideimzole – 5 – carbonyl) –pyridine – 2 – ile-amino] propionate and preparation Pharmacy containing it

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL163863A IL163863A (en) 2002-03-07 2004-09-01 Pharmaceutical composition for oral administration of 3-[(2 -{[4- (hexyloxycarbonylamino- imino- methyl)-phenylamino]methyl}-1- methyl-1h- benzimidazol-5- carbonyl)- pyridin- 2- yl- amino] propionic acid ethyl ester
IL209368A IL209368A (en) 2002-03-07 2010-11-17 Ethylsulfonate Salt of Ethyl 3 - [(2– {4– (xyloxycarbonylamino – amino – methyl) –phenylamino] –methyl} –1 – methyl – H1– benzamideimzole – 5 – carbonyl) –pyridine – 2 – ile-amino] propionate and preparation Pharmacy containing it

Country Status (36)

Country Link
US (2) US20190231766A1 (pt)
EP (2) EP1485094B2 (pt)
JP (3) JP3866715B2 (pt)
KR (1) KR101005716B1 (pt)
CN (1) CN100528157C (pt)
AR (2) AR042861A1 (pt)
AT (1) ATE540943T1 (pt)
AU (1) AU2003210400B8 (pt)
BR (1) BRPI0306559B8 (pt)
CA (1) CA2476054C (pt)
CL (1) CL2009001915A1 (pt)
CO (1) CO5611149A2 (pt)
CY (4) CY1112796T1 (pt)
DE (1) DE122012000047I1 (pt)
DK (2) DK1485094T4 (pt)
EA (1) EA009664B1 (pt)
EC (1) ECSP045331A (pt)
ES (2) ES2380704T3 (pt)
HK (1) HK1078792A1 (pt)
HR (1) HRP20040807B1 (pt)
IL (3) IL163863A0 (pt)
LU (2) LU92025I2 (pt)
ME (1) ME00325B (pt)
MX (1) MXPA04008542A (pt)
MY (1) MY143734A (pt)
NO (3) NO326918B1 (pt)
NZ (2) NZ535663A (pt)
PE (1) PE20030889A1 (pt)
PL (2) PL210862B1 (pt)
PT (2) PT1870100E (pt)
RS (1) RS52088B (pt)
SG (1) SG146435A1 (pt)
SI (2) SI1485094T2 (pt)
TW (1) TWI293879B (pt)
WO (1) WO2003074056A1 (pt)
ZA (1) ZA200406071B (pt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE10341043A1 (de) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
EP1757310A1 (en) * 2004-05-24 2007-02-28 Qualicaps Co., Ltd. Surface-modified and solubility-improved hard capsule
DE102004062864A1 (de) 2004-12-21 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Folienbehälter
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
CA2657270A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New paediatric indications for direct thrombin inhibitors
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
RU2010143901A (ru) * 2008-03-28 2012-05-10 Бёрингер Ингельхайм Интернациональ Гмбх (De) Способ получения композиций дабигатрана для перорального введения
WO2009118321A1 (de) * 2008-03-28 2009-10-01 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von säurepellets
NZ589746A (en) * 2008-07-14 2012-10-26 Boehringer Ingelheim Int Method for manufacturing medicinal compounds containing dabigatran
EP2309985B1 (en) 2008-07-28 2018-03-14 Takeda Pharmaceutical Company Limited Pharmaceutical composition
EP2328581A1 (en) * 2008-08-19 2011-06-08 Boehringer Ingelheim International GmbH Use of dabigatranetexilate for treating patients with pulmonary hypertension
BRPI0917507A2 (pt) * 2008-08-19 2015-11-17 Boehring Ingelheim Internat Gmbh dabigatrana para a caterização cardíaca percutânea intervencionista
JP2012526766A (ja) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍性及び線維性疾患の処置における新規な併用療法
TW201124143A (en) 2009-08-24 2011-07-16 Boehringer Ingelheim Int Emergency interventions of active charcoal with dabigatran etexilate overdosing
ES2509117T3 (es) * 2010-03-01 2014-10-17 Ratiopharm Gmbh Composición farmacéutica oral que contiene dabigatran etexilato
WO2011110478A1 (en) 2010-03-08 2011-09-15 Ratiopharm Gmbh Dabigatran etexilate-containing pharmaceutical composition
US20130177652A1 (en) 2010-07-01 2013-07-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
WO2012004397A1 (en) 2010-07-09 2012-01-12 Esteve Química, S.A. Intermediates and process for preparing a thrombin specific inhibitor
CN102985416B (zh) 2010-07-09 2015-04-01 埃斯特维化学股份有限公司 制备凝血酶特异性抑制剂的方法
HUE026408T2 (en) 2010-09-27 2016-06-28 Ratiopharm Gmbh Dabigatran etexylate bis-mesylate salt, solid forms and process for their preparation
EA201391758A1 (ru) * 2011-05-24 2014-06-30 Тева Фармасьютикал Индастриз Лтд. Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
EA201400737A1 (ru) * 2011-12-22 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
WO2013111163A2 (en) 2012-01-20 2013-08-01 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
EP2806858A1 (en) 2012-01-24 2014-12-03 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
RS62566B1 (sr) 2012-02-21 2021-12-31 Towa Pharmaceutical Europe S L Oralne farmaceutske kompozicije dabigatran eteksilata
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
EP2834224B1 (en) 2012-04-02 2018-06-06 MSN Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
CA2886094A1 (en) 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
US20150246899A1 (en) 2012-09-28 2015-09-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014060561A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
WO2014060545A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of dabigatran free base
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN103127109B (zh) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 含达比加群酯或其盐和水合物的药用组合
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物
EP2853260A1 (en) 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
WO2015145462A1 (en) 2014-03-26 2015-10-01 Cadila Healthcare Limited Pharmaceutical compositions of dabigatran
EP2929884A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CA3001495C (en) * 2014-11-03 2021-07-20 Solipharma Llc Formulations of dabigatran etexilate or dabigatran etexilate salts and preparation methods thereof
CN105640909B (zh) * 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
WO2016107605A1 (zh) 2014-12-31 2016-07-07 昆明积大制药股份有限公司 药物组合物及其制备方法
CN105797162B (zh) * 2014-12-31 2022-10-25 昆明积大制药股份有限公司 药用辅料表面改性方法
CN106924256B (zh) * 2015-12-25 2022-08-19 深圳市药欣生物科技有限公司 药物组合物及其制备方法
TR201502223A2 (tr) 2015-02-25 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve dabigatranın farmasötik kombinasyonları.
CN106999434B (zh) * 2015-04-08 2020-05-22 杭州领业医药科技有限公司 一种含半胱氨酸盐酸盐的微丸及其制备方法
MA42480A (fr) 2015-07-20 2018-05-30 Sanovel Ilac Sanayi Ve Ticaret As Préparations pharmaceutiques de dabigatran sous forme de base libre
CN105919962B (zh) * 2015-12-18 2019-01-18 重庆两江药物研发中心有限公司 一种达比加群酯片剂及其制备方法
EP3184102A1 (en) 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TR201606697A2 (tr) 2016-05-20 2017-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin yeni̇ oral farmasöti̇k formülasyonlari
TR201617984A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
WO2018104387A1 (en) 2016-12-07 2018-06-14 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayered tablet compositions of dabigatran
WO2018122262A1 (en) 2016-12-28 2018-07-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Bilayer tablet formulations of dabigatran etexilate
JP2018184375A (ja) 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
WO2018229784A1 (en) * 2017-06-14 2018-12-20 Natco Pharma Limited Pharmaceutical compositions of dabigatran
CN109125274A (zh) * 2017-06-28 2019-01-04 上海美悦生物科技发展有限公司 注射用苯并咪唑类药用酸组合物及其制备方法和用途
TR201722353A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatran eteksi̇lat i̇çeren oral uygulama i̇çi̇n farmasöti̇k formülasyon
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722186A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
TR201722630A2 (pt) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
KR20200082641A (ko) 2018-12-31 2020-07-08 주식회사 유영제약 다비가트란 에텍실레이트를 포함하는 약제학적 조성물
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
KR20210157691A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157692A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157693A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
CN115227663B (zh) * 2021-04-22 2023-12-12 石药集团恩必普药业有限公司 一种甲磺酸达比加群酯胶囊及其制备方法
WO2023139243A1 (en) 2022-01-21 2023-07-27 Adamed Pharma S.A A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran
GR1010399B (el) * 2022-04-05 2023-02-03 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιπηκτικο παραγοντα και μεθοδος παραγωγης αυτου

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) * 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

Also Published As

Publication number Publication date
NO326918B1 (no) 2009-03-16
DK1485094T3 (da) 2012-10-15
HRP20040807B1 (hr) 2014-11-21
ES2390661T3 (es) 2012-11-15
ME00325B (me) 2011-05-10
EA200401136A1 (ru) 2005-04-28
CN1638771A (zh) 2005-07-13
DK1870100T3 (da) 2012-05-14
KR20040099298A (ko) 2004-11-26
CY2012031I1 (el) 2015-08-05
WO2003074056A1 (de) 2003-09-12
AU2003210400B2 (en) 2008-08-07
NO20081304L (no) 2004-06-07
TW200306188A (en) 2003-11-16
EA009664B1 (ru) 2008-02-28
IL209368A0 (en) 2011-01-31
CA2476054C (en) 2011-11-08
PL394601A1 (pl) 2011-07-18
LU92117I2 (fr) 2013-02-19
NO2013001I2 (no) 2014-09-01
JP2005519099A (ja) 2005-06-30
BR0306559A (pt) 2004-11-30
NO332209B1 (no) 2012-07-30
JP4953727B2 (ja) 2012-06-13
AR072385A2 (es) 2010-08-25
NO20042361D0 (no) 2004-06-07
NZ535663A (en) 2006-06-30
CY2012020I1 (el) 2015-08-05
SG146435A1 (en) 2008-10-30
US20200085807A1 (en) 2020-03-19
ES2390661T5 (es) 2020-12-04
AR042861A1 (es) 2005-07-06
SI1485094T1 (sl) 2012-10-30
EP1485094A1 (de) 2004-12-15
MY143734A (en) 2011-07-15
CN100528157C (zh) 2009-08-19
CY2012020I2 (el) 2015-08-05
TWI293879B (en) 2008-03-01
IL209368A (en) 2012-10-31
NO20042361L (no) 2004-06-07
CO5611149A2 (es) 2006-02-28
JP3866715B2 (ja) 2007-01-10
PL210862B1 (pl) 2012-03-30
LU92025I2 (fr) 2012-08-20
HK1078792A1 (en) 2006-03-24
KR101005716B1 (ko) 2011-01-05
MXPA04008542A (es) 2004-12-06
DK1485094T4 (da) 2020-06-22
ECSP045331A (es) 2006-04-19
HRP20040807A2 (en) 2005-02-28
JP2007056018A (ja) 2007-03-08
PE20030889A1 (es) 2003-12-10
US20190231766A1 (en) 2019-08-01
EP1485094B2 (de) 2020-03-25
ATE540943T1 (de) 2012-01-15
BRPI0306559B1 (pt) 2021-05-18
PT1485094E (pt) 2012-10-09
SI1485094T2 (sl) 2020-08-31
CA2476054A1 (en) 2003-09-12
NZ546367A (en) 2008-08-29
RS52088B (sr) 2012-06-30
PL212566B1 (pl) 2012-10-31
IL163863A (en) 2013-02-28
AU2003210400A1 (en) 2003-09-16
ES2380704T9 (es) 2013-07-24
CY2012031I2 (el) 2015-08-05
CY1113158T1 (el) 2015-08-05
CL2009001915A1 (es) 2010-02-12
CY1112796T1 (el) 2015-08-05
ES2380704T3 (es) 2012-05-17
SI1870100T1 (sl) 2012-05-31
NO2013001I1 (no) 2013-02-11
JP2006328081A (ja) 2006-12-07
ZA200406071B (en) 2005-11-30
DE122012000047I1 (de) 2012-09-13
PT1870100E (pt) 2012-04-17
EP1870100B1 (de) 2012-01-11
MEP50708A (en) 2011-02-10
RS79204A (en) 2007-02-05
AU2003210400B8 (en) 2008-09-25
PL370517A1 (en) 2005-05-30
BRPI0306559B8 (pt) 2021-05-25
EP1870100A1 (de) 2007-12-26
EP1485094B1 (de) 2012-07-04

Similar Documents

Publication Publication Date Title
IL163863A0 (en) Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz
GB0109532D0 (en) Presentation of images
AU2003205950A8 (en) Placement of alternative advertisements
GB0220861D0 (en) Presentation of information
GB0202782D0 (en) Display
TW586639U (en) Expanding structure of display
GB2387984B (en) Display of enhanced content
PL1987819T3 (pl) Flupirtyna w postaci do iniekcji
GB0210659D0 (en) Display
AU2003298725A8 (en) Preparation of metallotexaphyrins
AU2003217354A8 (en) Synthesis of sulfamidates
IL165356A0 (en) Preparation of 4-haloalkylkylnicotinamides
PL356853A1 (en) Application of bacteriphages
HU0200158V0 (en) Arrangement for realization of exhibition
GB0210951D0 (en) Finger-lock display
GB0312028D0 (en) Manufacture of signs
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40
TW525447U (en) Structure of table
GB0222015D0 (en) Means of assembly-bozz 2
PL373284A1 (en) Analogues of vitamin d
EP1511485A4 (en) NOVEL USES OF I DL / I -TETRAHYDROPALMATIN
SI1509241T1 (sl) Nove uporabe cefaibolov
TW533774U (en) Structure improvement of flyswatter
TW543789U (en) Improved structure of projector
TW567775U (en) Structure of hairtie